These Simplywall AI estimates have already been discussed before, but they must be getting their evaluations from somewhere. Now Nexstim was in this kind of company on their site – Top 10 Undervalued Stocks Based On Cash Flows In Europe
19 Likes
Sinaptica at the MedTech World StartUp “village”. Hopefully, money will come pouring in, so we can get the research across the finish line quickly.
15 Likes
Hasn’t this popped up here yet? #keiretsubacked | Keiretsu Forum
5 Likes
That CABHI funding seems to have popped up a few times. If I recall correctly, it came through in November; I assume it’s the same money. A valuable partnership for Sinaptica in any case.
2 Likes
Sinaptica won the PitchForce Invest Summit 2026
45 Likes
A new page on brain mapping has been added to Brainlab’s website: Nexstim NBS System: Brain mapping with unparalleled accuracy | Brainlab
40 Likes
“Rolls-Royce of TMS machines”
32 Likes
Order from India
37 Likes
It’s great that there is interest in India and the device has been found useful, especially since it’s an existing customer. The EU-India trade agreement is now looking positive from Nexstim’s perspective as well. The market would be huge; fortunately, we’ve at least got a foot in the door…
27 Likes
As much as I would like to declare that Nexstim has once again taken a major leap forward, I suppose it must be admitted that a competitor’s device is in question.
1 Like
In a way, a Nexstim system could be sold alongside it to perform the mapping first, so that the treatment is easier and safer. That is, after all, a laser used to destroy the tumor.
26 Likes
Surely tumor removal has nothing to do with Nexstim’s device, except perhaps for the need for pre-operative mapping where Nexstim’s device is required?
Do you also go and comment on the Tesla stock thread when some “competing” company launches a new version of a forestry machine?
19 Likes
Agreed. Even though Nexstim’s devices operate in the head area, it doesn’t mean they can perform every treatment that happens in the dome. At least not yet.
To avoid this being a complete zero-effort post, I’ll link last month’s top 100 shareholder change statistics. At least Kyösti hasn’t continued selling, and the list of top names doesn’t look too bad otherwise.
10 Likes
The top 100 owners seem to be mainly on the buying side.
The largest seller appears to be at rank 94 and is likely the same person who wrote about their reductions on the KL forum. They will soon run out of shares to dump (they had 7,813 left at the turn of the month), and the fire sales will likely be over for a while.
I’m certainly waiting for the end of the month and the earnings release with interest. In my opinion, it is now quite clear that Inderes’ analysis is way off once again, as no diagnostic deals have been announced. I think it would be quite surprising if there were zero diagnostic deals in the last quarter, as Inderes has predicted.
Along with the earnings release, the first positive result will also be made public, and consequently, the stock will naturally start to attract a new kind of interest.
20 Likes
We also have to be prepared for the possibility that Inderes’ forecast hits the mark and there really are exactly zero deals. Sometimes the explanation is very simple and the answer is staring us right in the face when wondering why no diagnostic sales have been announced. The wait feels long with this semi-annual reporting.. 
9 Likes
Fresh research with Nexstim’s TMS-EEG.
Precision is increasing, and it may open up more opportunities in the future. If anyone on this forum is more familiar with the field, perhaps they could provide a slightly more detailed interpretation of the study for us laypeople. In any case, it’s great that research data on TMS-EEG is starting to emerge this quickly.
“These findings have important clinical implications, opening new opportunities for the individualization of therapeutic interventions.”
https://www.biorxiv.org/content/10.64898/2026.01.30.702764v1.full.pdf+html
9 Likes
MedTech World Middle East, taking place from 11 to 13 February
https://med-tech.world/news/meet-startups-and-exhibitors-medtech-world-middle-east-dubai-2026/
Sinaptica has its own “booth” in Dubai.
6 Likes
Well then, I wonder if those who took a beating from Opto and Faron today took profits from Nexstim… I was tempted to do the same myself 
or did anyone come across an explanation… ugly day, damn it..
3 Likes